Overall survival was significantly longer in the necitumumab plus gemcitabine and cisplatin group than in the gemcitabine and cisplatin alone group ( median 115 months [ 95 % CI 104-126 ] ) vs 99 months [ 89-111 ] ; stratified hazard ratio 084 [ 95 % CI 074-096 ; p = 001 ] ) .